A voice-based artificial intelligence platform to detect changes in health
A voice-based artificial intelligence platform to detect changes in health
Description
Puretech Ownership1
Stage of Development
A voice-based artificial intelligence platform to detect changes in health
35.2% Equity
COMMERCIAL RELEASE
Description
A voice-based artificial intelligence platform to detect changes in health
Puretech Ownership1
35.2% Equity
Stage of Development
COMMERCIAL RELEASE
1 As of June 30, 2023, PureTech’s percentage ownership of Sonde was approximately 35.2% on a partially diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans.

A voice-based artificial intelligence platform to detect changes in health

Sonde is developing a voice-based technology platform that detects changes in the sound of voice that are linked to health conditions – like depression, anxiety and respiratory disease – to provide health tracking and monitoring. Sonde’s proprietary technology can be integrated into ubiquitous devices such as smartphones, headphone and smart speakers.
  • Program Discovery Process by the PureTech Team
    • We identified vocal features as a leading non-invasive source of health data, particularly given the evolving technology landscape where voice interactions with devices are rapidly increasing and in-licensed proprietary technology from Thomas Quatieri, Ph.D., at MIT’s Lincoln Laboratory in May 2016. We developed additional, novel intellectual property around this concept and helped advance the technology from an academic concept to a commercially focused technology.
  • Milestones Achieved & Developmental Status
  • Expected Milestones
Note: Sonde has obtained Institutional Review Board (IRB) approval independently or in collaboration with partner institutions that covers all past and ongoing human data collection for research in the U.S. and abroad. We have two board designees on the board of directors of Sonde, but Sonde has its own independent management team. Our role in the development of Sonde’s therapeutic candidates is through our representation on its board of directors and our role as a majority shareholder. Sonde is well-protected with a robust intellectual property portfolio. Sonde was incorporated in February 2015.
Sonde launched Sonde Mental Fitness, a voice-enabled mental health detection and monitoring technology that uses a brief voice sample to evaluate mental well-being, and has initiated research and development to expand its proprietary technology into mental fitness, respiratory disease, and other health, wellness and safety use cases. Additionally, the company’s Vocal Biomarker program has demonstrated the potential to screen and monitor for disease using information obtained from an individual’s voice on commonly owned devices, such as smartphones and smart speakers, and it has the potential to fundamentally change the way mental and physical health is screened and monitored.